系统性硬化症中显性与亚临床左心室收缩功能障碍的预后与功能意义
基于澳大利亚硬皮病队列研究,纳入符合ACR/EULAR标准且有左室射血分数(LVEF)测量的系统性硬化症(SSc)患者,评估显性及亚临床左心室收缩功能障碍的频率与临床意义。结果显示LVEF<50%与LV-GLS受损均与更差生存及身体功能受损相关,且LVEF持续正常者中LV-GLS异常频率提示被低估的细微收缩功能障碍负担。
要点
- 在无共存心脏病SSc患者中,LVEF<50%者占2.4%,LVEF≤40%者仅0.6%。
- 单中心218例中21%存在LV-GLS受损(>-16%) despite LVEF≥50%。
- LVEF<50%与死亡率升高相关(HR2.3,95%CI1.0-4.8,p=0.04)。
核心结论
- 显性与亚临床SSc相关左心室功能障碍均与更差生存及身体功能受损相关。
- LVEF持续正常者中LV-GLS异常频率提示SSc中细微左室收缩功能障碍负担被低估,并对患者症状有显著影响。
研究设计与样本
- 澳大利亚硬皮病队列研究,纳入符合ACR/EULAR标准且有≥1次超声心动图LVEF测量的SSc参与者。
- 排除继发性左室功能障碍原因(心肌缺血、瓣膜病和肺动脉高压)者。
- 采用卡方检验、两样本t检验或Wilcoxon秩和检验进行组间比较,广义估计方程(GEE)建模纵向数据,Kaplan-Meier和Cox比例风险模型用于生存分析。
主要发现
- 1141例无共存心脏病参与者中,2.4%曾记录LVEF<50%,仅0.6%曾记录LVEF≤40%。
- 单中心90%参与者(n=218)有LV-GLS数据,其中21%尽管LVEF≥50%仍检测到LV-GLS受损。
- LVEF<50%者更常见男性(p=0.01)、dcSSc(p<0.01)、更高炎症标志物(p<0.02)和骨骼肌疾病(p<0.05)。
- 多变量分析中,记录LVEF<50%与死亡率升高相关(HR2.3,95%CI1.0-4.8,p=0.04);LV-GLS受损在单变量分析中亦与更差生存相关(HR3.4,95%CI1.0-11.8,p=0.05)。
- LVEF<50%者更常见WHO III/IV级呼吸困难(OR3.5,95%CI1.6-7.7,p<0.01),六分钟步行距离更短(p=0.01),健康评估问卷-残疾指数评分更高(p<0.01),SF-36躯体成分 summary评分更低(p=0.02);LV-GLS受损者亦见呼吸困难增加(WHO III/IV级呼吸困难;OR3.6,95%CI1.4-9.2,p<0.01)。
关键数值与推荐
- 显性左室功能障碍定义为LVEF降低;亚临床左室功能障碍定义为LV-GLS受损(LV-GLS>-16%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To quantify the frequency and clinical implications of systemic sclerosis (SSc)-associated left ventricular function (LV) impairment. METHODS: Australian Scleroderma Cohort Study participants meeting ACR/EULAR criteria for SSc with ≥1 echocardiographic LVEF measurement were included. Overt LV dysfunction was indicated by reduced LV ejection fraction (LVEF) and subclinical LV dysfunction was measured using impaired LV global longitudinal strain (LV-GLS>-16 %). Those with secondary causes of LV dysfunction (myocardial ischaemia, valvulopathy and pulmonary arterial hypertension) were excluded. Chi-squared tests, two-sample t-tests or Wilcoxon rank-sum tests were used for between-group comparison as appropriate. Generalised estimating equations(GEE) were used to model longitudinal data. Kaplan-Meier and Cox proportional hazard models were used for survival analyses. RESULTS: Of 1141 participants with no co-morbid cardiac disease, 2.4 % ever recorded a LVEF<50 %, while only 0.6 % ever recorded a LVEF≤40 %. LV-GLS data were available for 90 % of participants at one centre (n = 218). Impaired LV-GLS was detected in 21 % despite LVEF≥50 %. Those with a LVEF<50 % were more frequently male (p = 0.01) with dcSSc (p < 0.01), higher inflammatory markers (p < 0.02) and skeletal muscle disease (p < 0.05). In multivariable analyses, recording a LVEF<50 % was associated with increased mortality (HR2.3, 95 %CI1.0-4.8, p = 0.04). Impaired LV-GLS was also associated with poorer survival in univariable analyses (HR3.4, 95 %CI1.0-11.8, p = 0.05). Those with a LVEF<50 % more frequently recorded WHO Class III/IV dyspnoea (OR3.5, 95 %CI1.6-7.7, p < 0.01), with shorter six-minute walk distance (p = 0.01), higher Health Assessment Questionnaire-Disability Index scores (p < 0.01) and lower Short Form-36 Physical Component Summary scores (p = 0.02). Increased dyspnoea (WHO Class III/IV dyspnoea; OR3.6, 95 %CI1.4-9.2, p < 0.01) was also seen in those with impaired LV-GLS. CONCLUSIONS: Both overt and subclinical SSc-associated LV dysfunction are associated with worse survival and impaired physical function. The frequency of abnormal LV-GLS in those with consistently normal LVEF suggests an under-appreciated burden of subtle LV systolic dysfunction in SSc that has a significant impact on patient symptomatology.
引用
- Fairley JL, Hansen D, Proudman S, et al. Prognostic and functional importance of both overt and subclinical left ventricular systolic dysfunction in systemic sclerosis. Semin Arthritis Rheum. 2024. PMID: 38631275. doi:10.1016/j.semarthrit.2024.152443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。